Search "Ozempic shortage" today and you'll find headlines and forum posts from every point in a three-year saga — some of them a year or two old, some from last month. That makes it genuinely hard to tell what's actually true right now. Here's the short version: the shortage that defined 2022 through early 2025 is officially over, but "officially over" and "easy to find at every pharmacy" are two different things. This guide separates what's settled from what's still messy, so you know what you're actually dealing with.
1. Is Ozempic Officially "In Shortage"?
No. The FDA's Drug Shortages Database lists the semaglutide injection shortage — covering both Ozempic and Wegovy — as resolved effective February 21, 2025. That followed an earlier determination in October 2024 that supply had caught up with demand, and it closed out a shortage that had officially been on the books since August 2022.
What "resolved" doesn't mean: it doesn't mean every pharmacy has every dose in stock every day. Independent pharmacy-stock tracking has continued to show low real-world availability scores for Ozempic at various points in 2026, even with no active FDA shortage designation. The gap between "not in shortage" and "easy to fill" is exactly where most patient frustration in 2026 comes from.
2. Why Stockouts Still Happen After the Shortage Ended
A few things are true at once, and none of them require an active national shortage to explain what you're seeing at the counter.
- Demand hasn't leveled off. More prescribers are using semaglutide for type 2 diabetes, and off-label demand for weight loss continues to grow well beyond what was anticipated when manufacturing capacity was expanded.
- Distribution is uneven. Individual pharmacy locations, even within the same chain, receive different shipment volumes. One CVS or Walgreens can be fully stocked while another a few miles away is out of the exact dose you need.
- Starter doses are disproportionately affected. New patients starting on 0.25 mg or 0.5 mg pens report more difficulty than existing patients refilling a 1 mg or 2 mg maintenance dose.
- The compounding shutdown redirected demand. Patients who had been using lower-cost compounded semaglutide during the shortage largely had to move back to brand-name product once compounding allowances ended in 2025, adding to demand on the commercial supply.
3. Timeline: How We Got Here
| Date | Event |
|---|---|
| August 2022 | FDA first lists injectable semaglutide (Ozempic/Wegovy) as being in shortage |
| 2022–2024 | Nationwide stockouts; FDA permits 503A/503B compounding pharmacies to produce semaglutide |
| October 2024 | FDA determines available supply now meets national demand |
| February 21, 2025 | FDA officially closes the semaglutide injection shortage |
| April 22, 2025 | 503A compounding pharmacies lose their allowance to compound semaglutide |
| May 22, 2025 | 503B outsourcing facilities lose the same allowance |
| 2025–2026 | Novo Nordisk and Eli Lilly pursue legal action against telehealth platforms and compounders still selling GLP-1 products; litigation continues into mid-2026 |
| Mid-2026 | No active shortage designation; availability remains geography- and dose-dependent |
4. Current Availability by Dose
| Dose | Typical use | General availability |
|---|---|---|
| 0.25 mg pen | Starter dose, new patients | Most likely to be intermittently out of stock |
| 0.5 mg pen | Starter/early titration dose | Intermittently out of stock in some regions |
| 1 mg pen | Maintenance dose | Generally available at most chain pharmacies |
| 2 mg pen | Higher maintenance dose | Generally available at most chain pharmacies |
| Oral tablet (Rybelsus-line reformulation) | Alternative to injection | Availability varies by pharmacy; newer to the market |
Availability also varies significantly by pharmacy type. Independent pharmacies sometimes source from different wholesalers than large national chains, which means it's worth calling a local independent pharmacy if your usual big-box chain is out.
5. The Compounding Crackdown
This is the part of the 2026 story that trips people up the most, because compounded semaglutide was such a common workaround during the shortage years.
Compounded semaglutide is no longer legal for routine, general dispensing. Once the FDA declared the shortage resolved, the temporary allowances that let 503A pharmacies and 503B outsourcing facilities compound copies of semaglutide expired — April 22, 2025 for 503A, May 22, 2025 for 503B. Compounding is still permitted in narrow, patient-specific circumstances, such as a documented medical need for a different strength or a formulation that isn't commercially manufactured, but it can no longer be used simply because brand Ozempic costs more or is temporarily hard to find.
That legal shift hasn't been quiet. Manufacturers have pursued litigation against telehealth platforms and compounding pharmacies they allege continued selling unapproved semaglutide products after the grace periods ended, and federal regulators have separately raised concerns about adverse events tied to some compounded GLP-1 products sold during and after the shortage. If you're offered compounded semaglutide today outside of a documented clinical-need exception, treat that as a red flag rather than a convenience.
6. Legal Alternatives If Your Pharmacy Is Out
| Alternative | What it is | Key consideration |
|---|---|---|
| Wegovy | Same active ingredient (semaglutide), higher doses | FDA-approved for weight management, not type 2 diabetes; insurance coverage differs |
| Rybelsus / oral semaglutide | Same drug class, taken as a pill | Skips the injection, but daily dosing and food-timing rules apply |
| Mounjaro / Zepbound (tirzepatide) | Related but distinct GLP-1/GIP dual agonist | Not a direct substitution — requires a new prescription and prescriber discussion |
| Trulicity or Victoza | Other GLP-1 receptor agonists for type 2 diabetes | Different dosing schedules; discuss with your prescriber before switching |
| Compounded semaglutide | Custom-compounded copy | Legal only for a narrow, documented clinical-need exception — not a general substitute |
7. Step-by-Step: What to Do If You Can't Find It
Call ahead before your fill date
Call your pharmacy a few days before you're due for a refill to confirm they have your specific dose in stock, rather than finding out when you arrive.
Check independent pharmacies nearby
Independent pharmacies sometimes have different supply chains than large chains and may have stock when a nearby CVS or Walgreens doesn't.
Ask your prescriber about dose flexibility
If your exact starter dose is unavailable, your prescriber may be able to adjust your prescription to a dose strength that's currently in stock.
Confirm insurance coverage before switching products
If you're considering an alternative like Mounjaro or Rybelsus, check your plan's formulary and prior-authorization rules first, since coverage and step-therapy requirements differ by product.
Never ration doses on your own
If you're at real risk of running out, contact your prescriber or pharmacist rather than stretching your supply by skipping or splitting doses — GLP-1 dosing changes should be guided by a clinician.
8. Cost: List Price, Savings Card & Assistance
Cost and availability are separate problems, but they compound each other for a lot of patients. Here's where pricing stands as of this update.
| Situation | Typical monthly cost |
|---|---|
| List price / full cash price | Roughly $935–$1,000, varying by dose and pharmacy |
| Commercially insured, with NovoCare Savings Card | As low as $25/month for eligible patients |
| Commercially insured, without the savings card | Often $100–$400+ depending on formulary tier |
| Medicare Part D (type 2 diabetes) | Typically lower than in past years following IRA-related price negotiations, though it still varies by plan |
| Uninsured, qualifying for the Patient Assistance Program | Free for eligible patients under roughly 400% of the federal poverty level |
Important limits on the NovoCare Savings Card: it's a copay-assistance card, not a cash-price coupon, so it only reduces what you owe after your commercial insurance processes the claim. It cannot be combined with Medicare, Medicaid, Tricare, or VA benefits, and it cannot be stacked with other discount programs like GoodRx at the same fill.
Novo Nordisk has publicly signaled an intent to lower Ozempic's list price to roughly $675 per month, though the exact timing of that change had not been confirmed as of this update — treat it as a direction, not a date you can rely on yet.
9. Decision Tree: What Should You Do Right Now?
If you're close to running out, reach your care team the same day to discuss a temporary alternative rather than skipping or reducing doses on your own.
Need help affording GLP-1 medications? See our related guides: